WINTON GROUP Ltd Buys 29,124 Shares of Progyny, Inc. (NASDAQ:PGNY)

WINTON GROUP Ltd increased its position in shares of Progyny, Inc. (NASDAQ:PGNY) by 62.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 75,515 shares of the company’s stock after purchasing an additional 29,124 shares during the quarter. WINTON GROUP Ltd’s holdings in Progyny were worth $1,303,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of PGNY. Signaturefd LLC raised its position in shares of Progyny by 1,355.0% in the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company’s stock valued at $25,000 after buying an additional 1,355 shares in the last quarter. GAMMA Investing LLC lifted its stake in Progyny by 341.4% during the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock worth $28,000 after purchasing an additional 1,246 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Progyny by 108.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock valued at $51,000 after purchasing an additional 1,526 shares in the last quarter. Caitlin John LLC boosted its holdings in shares of Progyny by 2,974.8% in the 4th quarter. Caitlin John LLC now owns 3,290 shares of the company’s stock valued at $57,000 after purchasing an additional 3,183 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in shares of Progyny during the 4th quarter worth $74,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Price Performance

PGNY opened at $22.31 on Friday. Progyny, Inc. has a fifty-two week low of $13.39 and a fifty-two week high of $38.98. The company’s 50 day moving average price is $22.05 and its two-hundred day moving average price is $18.58. The firm has a market capitalization of $1.91 billion, a price-to-earnings ratio of 38.47, a PEG ratio of 2.39 and a beta of 1.41.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Bank of America raised their price objective on Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. JPMorgan Chase & Co. lifted their price target on shares of Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Finally, Canaccord Genuity Group increased their price objective on shares of Progyny from $17.00 to $23.00 and gave the company a “hold” rating in a research note on Friday, February 28th. Nine investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $24.82.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.